



**Holista CollTech Limited**

(ASX:HCT / ABN 24 094 515 992)

283 Rokeby Road Subiaco WA 6008

**P:** +61 8 6141 3500 ; **F:** +61 8 6141 3599 **W:** [www.holistaco.com](http://www.holistaco.com)

## **ASX Announcement**

**27 July 2018**

### **HOLISTA COLLTECH LIMITED APPENDIX 4C QUARTERLY REPORT**

Holista CollTech Limited (**Holista**, or **the Company**) (ASX CODE: HCT) is pleased to release the Appendix 4C for the quarter ending 30 June 2018.

“We are pleased to show a positive cash position this quarter”, says Dr Rajen Manicka, Managing Director. “This result is on the back of improved operations in Holista’s various businesses across the world. The Company has enjoyed significant progress in the production and distribution of Holista’s Low GI and Gluten free range of food ingredients into North America (please refer to recent announcements) and the supplements business continues to grow in its markets. The Company anticipates strong growth in the noodle market toward the final quarter of 2018.”

“Collagen remains a strong focus for Holista. The Company has worked through recent technical matters that are being resolved. During the next half of 2018 collagen is expected to contribute to the Company’s growth profile,” commented Dr Rajen.

The Company has been able to manage this growth form internal funding.

With the various Company businesses across the world gathering momentum, on 26<sup>th</sup> June 2018, Holista announced a Share Purchase Plan(“SPP”). Shareholders have been extremely supportive with their participation in the SPP and shareholders need to be aware that today is the last day for them to take up their entitlement. If shareholders wish to participate then they should ensure all funds are sent today.

**ENDS**

**For further information, please contact:**

#### **Corporate Affairs & Business Opportunities**

Dr Rajen Manicka: [rajen.m@holistaco.com](mailto:rajen.m@holistaco.com)

General Enquiries: [enquiries@holistaco.com](mailto:enquiries@holistaco.com)

#### **Australia**

283 Rokeby Road

Subiaco WA 6008

**P:** +61 8 6141 3500 ; **F:** +61 8 6141 3599

#### **Malaysia**

12th Floor, Amcorp Trade Centre, PJ Tower

No. 18, Persiaran Barat off Jalan Timur

46000, Petaling Jaya, Malaysia

**P:** +603 7965 2828 ; **F:** +603 7965 2777

### **Media and Investor Relations Enquiries**

WeR1 Consultants Pte Ltd

3 Phillip Street #12-01

Singapore 048693

Roshan Singh, [roshansingh@wer1.net](mailto:roshansingh@wer1.net); P: +65 67374844

### **About Holista CollTech Ltd**

Holista CollTech Ltd (**Holista**) is a research-driven biotech company and is the result of the merger of Holista Biotech Sdn Bhd and CollTech Australia Ltd. Headquartered in Perth with extensive operations in Malaysia, Holista is dedicated to delivering first-class natural ingredients and wellness products and leads in research on herbs and food ingredients.

Holista, listed on the Australia Securities Exchange, researches, develops, manufactures and markets “health-style” products to address the unmet and growing needs of natural medicine. Holista’s suite of ingredients is capable of serving the industry to provide low-GI baked products, low sodium salt, low fat fried foods and low calories sugar without compromise in taste, odour and mouth feel. It is the only company to produce sheep (ovine) collagen using patented extraction methods.

# Appendix 4C

## Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

**HOLISTA COLLTECH LIMITED (ASX:HCT)**

ABN

**24 094 515 992**

Quarter ended (Current quarter)

**30 June 2018**

### Consolidated statement of cash flows

|  | Current<br>quarter<br>\$A'000 | Year to date<br>(6 Months)<br>\$A'000 |
|--|-------------------------------|---------------------------------------|
| <b>1. Cash flows from operating activities</b>             |                               |                                       |
| 1.1 Receipts from customers                                | 2,276                         | 3,781                                 |
| 1.2 Payments for:  | -                             | -                                     |
| (a) research and development <sup>‡</sup>                  | (52)                          | (74)                                  |
| (b) product manufacturing and operating costs <sup>‡</sup> | (768)                         | (1,218)                               |
| (c) advertising and marketing <sup>‡</sup>                 | (117)                         | (202)                                 |
| (d) leased assets  | -                             | -                                     |
| (e) staff costs  | (898)                         | (1,638)                               |
| (f) administration and corporate costs <sup>‡</sup>        | (230)                         | (791)                                 |
| 1.3 Dividends received (see note 3)                        | -                             | -                                     |
| 1.4 Interest received                                      | -                             | -                                     |
| 1.5 Interest and other costs of finance paid               | (24)                          | (44)                                  |
| 1.6 Income taxes (paid) / refunded                         | (11)                          | (21)                                  |
| 1.7 Government grants and tax incentives                   | -                             | -                                     |
| 1.8 Other (provide details if material)                    | -                             | -                                     |
| <b>1.9 Net cash from / (used in) operating activities</b>  | <b>176</b>                    | <b>(207)</b>                          |
| <b>2. Cash flows from investing activities</b>             |                               |                                       |
| 2.1 Payments to acquire:                                   |                               |                                       |
| (a) property, plant and equipment                          | (101)                         | (102)                                 |
| (b) businesses (see item 10)                               | -                             | -                                     |
| (c) investments  | -                             | -                                     |
| (d) intellectual property <sup>‡</sup>                     | -                             | (8)                                   |
| (e) other non-current assets                               | -                             | -                                     |
| 2.2 Proceeds from disposal of:                             |                               |                                       |
| (a) property, plant and equipment                          | -                             | -                                     |
| (b) businesses (see item 10)                               | -                             | -                                     |
| (c) investments  | -                             | -                                     |
| (d) intellectual property                                  | -                             | -                                     |
| (e) other non-current assets                               | -                             | 271                                   |
| 2.3 Cash flows from loans to other entities                | -                             | -                                     |
| 2.4 Dividends received (see note 3)                        | -                             | -                                     |
| 2.5 Other (provide details if material):                   | -                             | -                                     |
| <b>2.6 Net cash from / (used in) investing activities</b>  | <b>(101)</b>                  | <b>161</b>                            |

<sup>‡</sup> Year to date balances have been adjusted from March 2018 quarterly to correct allocation of payments. Total operating cash flows and total cash flows are unaffected.

| <b>Consolidated statement of cash flows</b>  | <b>Current quarter<br/>\$A'000</b>   | <b>Year to date<br/>(6 Months)<br/>\$A'000</b> |
|--|--|--|
| <b>3. Cash flows from financing activities</b>   |  |  |
| 3.1 Proceeds from issues of shares   | -  | -  |
| 3.2 Proceeds from issue of convertible notes   | -  | -  |
| 3.3 Proceeds from exercise of share options  | -  | -  |
| 3.4 Transaction costs related to issues of shares, convertible notes or options  | -  | -  |
| 3.5 Proceeds from borrowings   | (10)   | 75   |
| 3.6 Repayment of borrowings  | -  | -  |
| 3.7 Transaction costs related to loans and borrowings  | -  | -  |
| 3.8 Dividends paid   | -  | -  |
| 3.9 Other (provide details if material)  | -  | -  |
| <b>3.10 Net cash from / (used in) financing activities</b>   | <b>( 10)</b>   | <b>75</b>                                      |
| <b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>  |  |  |
| 4.1 Cash and cash equivalents at beginning of quarter/year to date   | 92   | 121  |
| 4.2 Net cash from / (used in) operating activities (item 1.9 above)  | 176  | (207)  |
| 4.3 Net cash from / (used in) investing activities (item 2.6 above)  | (101)  | 161  |
| 4.4 Net cash from / (used in) financing activities (item 3.10 above)   | ( 10)  | 75   |
| 4.5 Effect of movement in exchange rates on cash held  | 1  | 8  |
| <b>4.6 Cash and cash equivalents at end of quarter</b>   | <b>158</b>   | <b>158</b>                                     |
| <b>5. Reconciliation of cash and cash equivalents</b><br>at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts | <b>Current quarter<br/>\$A'000</b>   | <b>Previous quarter<br/>\$A'000</b>            |
| 5.1 Bank balances  | 158  | 92   |
| 5.2 Call deposits  | -  | -  |
| 5.3 Bank overdrafts  | -  | -  |
| 5.4 Other (provide details)  | -  | -  |
| <b>5.5 Cash and cash equivalents at end of quarter</b> (should equal item 4.6 above)   | <b>158</b>   | <b>92</b>                                      |
| <b>6. Payments to directors of the entity and their associates</b>   |  | <b>Current quarter<br/>\$A'000</b>             |
| 6.1 Aggregate amount of payments to these parties included in item 1.2   |  | 67   |
| 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3 and 2.5   |  | -  |
| 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2   | In respect to 6.1: Salaries and consulting fees paid to directors and their related parties. |  |
| <b>7. Payments to related entities of the entity and their associates</b>  |  | <b>Current quarter<br/>\$A'000</b>             |
| 7.1 Aggregate amount of payments to these parties included in item 1.2   |  | -  |
| 7.2 Aggregate amount of cash flow from loans to these parties included in items 2.3  |  | -  |
| 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2   | Nil  |  |

| <b>8. Financing facilities available</b><br>Add notes as necessary for an understanding of the position  | <b>Total facility amount at quarter end<br/>\$A'000</b> | <b>Amount drawn at quarter end<br/>\$A'000</b> |
|--|---|--|
| 8.1 Loan facilities  | 511   | 511  |
| 8.2 Credit standby arrangements  | 268   | 246  |
| 8.3 Other (please specify)   | -   | -  |
| 8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well. |   |  |

Loan facilities-This is secured term loan with RHB bank in Malaysia, interest rates ranging from 4.76% to 6.73%.  
Credit standby arrangements-This is banker acceptance bears interest of 5.15% with CIMB bank in Malaysia. This is secured loan by pledging fixed deposits.

| <b>9. Estimated cash outflows for next quarter</b> | <b>\$A'000</b> |
|--|----------------|
| 9.1 Research and development                       | 50             |
| 9.2 Product manufacturing and operating costs      | 1,070          |
| 9.3 Advertising and marketing                      | 150            |
| 9.4 Leased assets                                  | -              |
| 9.5 Staff costs                                    | 759            |
| 9.6 Administration and corporate costs             | 249            |
| 9.7 Other (provide details if material):           |                |
| <b>9.8 Total estimated cash outflows</b>           | <b>2,278</b>   |

| <b>10. Acquisitions and disposals of business entities</b><br>(items 2.1(b) and 2.2(b) above) | <b>Acquisitions</b>              | <b>Disposals</b> |
|---|----------------------------------|------------------|
| 10.1 Name of entity   | Holista Foods Canada Inc.        | -                |
| 10.2 Place of incorporation or registration   | Canada                           | -                |
| 10.3 Consideration for acquisition or disposal  | <i>Incorporate, not acquired</i> | -                |
| 10.4 Total net assets / (deficiency)  | -                                | -                |
| 10.5 Nature of business   | Food Ingredients                 | -                |

## Compliance statement

- This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- This statement gives a true and fair view of the matters disclosed.

Signed: \_\_\_\_\_ Dated: Friday, 27 July 2018

Company Secretary

Print name: BRETT FRASER

## Notes

- The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
- If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.